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We evaluated the sensitivity for colorectal cancer (CRC) of the latex agglutination test (LAT), an immunochemical test routinely used
in the Florence District screening programme since 2000. Sensitivity was calculated by the proportional interval cancer incidence
method in a population of 27503 consecutive subjects screened in 2000–2002, interval cancers being identified by linkage to the
Tuscany Cancer Registry files. Sensitivity was calculated overall and by gender, age, time since last negative LAT, CRC site, and rank of
screening. Overall 1- and 2-year sensitivity estimates were 80.7 and 71.5%, respectively, suggesting that faecal occult blood testing
screening sensitivity may be suboptimal due to testing or programme quality problems. Increasing screening sensitivity might be
achieved if the detection rate of advanced adenomas could be increased without unacceptable loss in specificity.
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Screening for colorectal cancer (CRC) by faecal occult blood
testing (FOBT) has been effective in reducing CRC mortality and
incidence (Towler et al, 2000), and is recommended in several
countries as current health policy. Randomised trials demonstrat-
ing FOBT screening effectiveness used a 3-day guaiac-based test
(G-FOBT), a chemical test based on haemoglobin peroxidase-like
activity whose accuracy is affected by dietary factors such as the
presence of nonhuman haemoglobin and peroxidases in vegeta-
bles, or by certain drugs, particularly NSAIDs. Sensitivity of
G-FOBT for CRC has been reported to be as low as 43–66%, based on
a 2-year screening interval (Jensen et al, 1992; Launoy et al, 1997;
Moss et al, 1999; Jouve et al, 2001); attempts to increase sensitivity
either by rehydration (Church et al, 1997) or by increased reagent
concentration (Petrelli et al, 1994; Allison et al, 1996) were
associated with unacceptable loss in specificity. Several studies
have suggested that immunochemical FOBT (I-FOBT) is more
sensitive and specific than G-FOBT (Castiglione et al, 1997; Saito
et al, 2000; Zappa et al, 2001; Levi et al, 2006; Guittet et al, 2007),
requiring no dietary restrictions, and might substantially improve
screening cost effectiveness (Castiglione et al, 1997; Saito et al,
2000). Further progress in I-FOBT use was made by the
introduction of the latex agglutination test (LAT), a quantitative
and fully automated test (Yamamoto et al, 1990), which made it
possible to choose the positivity cutoff values to optimise the
balance between sensitivity and specificity, though the debate
about the optimal cutoff point continues (Itoh et al, 1996;
Castiglione et al, 2000; Nakama et al, 2001; Edwards, 2005; Vilkin
et al, 2005). Sensitivity of G-FOBT and a previously used I-FOBT
(reversed passive haemagglutination (RPHA)) for CRC, based on
proportional interval cancer incidence, was determined previously
(Zappa et al, 2001). In the present study we have evaluated LAT
sensitivity using similar methodology.
POPULATION AND METHODS
Setting
A population-based FOBT screening programme has existed in
Florence District since 1982, run by the Istituto Scientifico per la
Prevenzione Oncologica (CPSO), its efficacy in reducing CRC
mortality supported by a case–control study (Zappa et al, 1997).
Reversed passive haemagglutination was used to replace G-FOBTin
1995 (Castiglione et al, 1997). A further study (Castiglione et al,
2000) showed that LAT (OC-Hemodia, developed with the OC-
Sensor instrument, Eiken, Tokyo, Japan, and henceforth referred
to as LAT) had a performance comparable with RPHA, and it was
adopted as the standard test in our programme in January 2000,
with a positivity threshold of 100ng Hbml
 1 of sample solution.
The main features and protocol have been reported in detail
(Grazzini et al, 2004). Colonoscopy was recommended to FOBT-
positive subjects.
Population
Subjects aged 50–70, living in 19 municipalities in the Province of
Florence, and attending FOBT screening from January 2000 to
December 2002 were eligible for the present study.
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identified by linking the Tuscany Cancer Registry (http://
www.cspo.it/REGISTRI//REGISTRO_RTT/rapporti/index.html)
(by name, date, and place of birth), with screening archives. In case
of partial matching (i.e. name and date of birth, not place of birth),
manual assessment of records was performed. All CRCs diagnosed
within 2 years after (1) a negative-LAT test or (2) a positive screen
followed by a negative assessment, were regarded as interval
cancers. Only interval cancers following a negative LAT were used
to calculate ‘screening test sensitivity’, whereas both classes of
interval cancers were used to assess ‘screening programme
sensitivity’. In this way, the limits of the test were distinguished
from those of the programme and the present figures compared
with similar estimates in the literature.
In the sensitivity assessment, LAT-positive (LATþ) cases who
refused assessment but had CRC diagnosed within 1 year since
LAT were regarded as being detected by the programme, whereas
cases with CRC diagnosed after 1 year were excluded. Screen
detected and interval CRCs were classified according to bowel
subsite and Dukes staging.
Statistical analysis
Sensitivity was estimated by the proportional interval cancer
incidence method (Day, 1985) which compares interval cancers
within a given interval following a negative screening, or a positive
test followed by a negative assessment, with the expected cancer
incidence in the absence of screening (underlying incidence)
according to the formula:
sensitivity ¼ 1  ð IðtÞ=IÞ
where I(t) is the observed interval cancers during interval t and I is
the underlying incidence. Person-years at risk were calculated
from the date of the first negative LAT. Observation ended (a) at 2
years, or (b) at interval cancer occurrence, or (c) at death from any
cause, or (d) at the end of the study (December 2003), or (e) at the
date of subsequent LAT if performed after an interval shorter than
2 years. Underlying CRC incidence was calculated using person-
years and age-/sex-specific incidence rates provided by the
Tuscany Cancer Registry (Table 1). Sensitivity was estimated both
overall and by gender, age (50–59 or 60–70) at LAT, time since
last negative LAT (first or second year of the interval), cancer
location (rectum and rectosigmoid junction: ICDO¼154; colon:
ICDO¼153), and rank of screening (first or subsequent).
Confidence intervals (95% CI) were calculated on the basis of
the exact Poisson’s distribution, while statistical differences among
strata (i.e. gender, age, site, time since last test, rank of screening)
were tested by Gaussian approximation of the log likelihood
(Clayton and Hills, 1993). Rate ratios (RRs) among strata were
computed.
RESULTS
From January 2000 to December 2002, 24913 subjects performed
27503 LATs, attendance rates in our programme being about 50%
in the study period. Age/sex distribution of subjects at the time of
the LAT are shown in Table 2. Table 3 presents LAT positivity and
detection rates of colorectal lesions. Overall, LAT was positive in
1097 of 27503 attending subjects (4.0%). Further diagnostic work-
up was refused by 138 (12.6%) and accepted by 959 of 1097 LATþ
subjects. Colonoscopy was complete in 788 of the 959 (82.2%) and
was incomplete in the remaining (17.3%). Double contrast barium
enema was performed with incomplete colonoscopy in 106 of
166 (63.9%) subjects, and alone in five of 959 LATþ cases (0.5%)
not complying with colonoscopy and referred to their family
physicians for diagnostic work up.
A total of 65 cancers were detected at screening, a detection rate
of 2.4%. Screen-detected CRCs’ Dukes stage was A, B, C, and D
in 30, 16, 11, and six subjects respectively; two screen-detected
neoplasms were carcinoids. Two cancers detected within 1 year
from a positive-LAT case who had refused colonoscopy in our
reference centres were regarded as screen-detected cancers.
Advanced adenoma(s) (larger than 9mm, or with high-grade
dysplasia, or with villous component X20%) was detected in 219
subjects.
For calculation of programme sensitivity 136 FOBTþ subjects
refusing assessment were excluded; two of them had CRC detected
after 1 year, and within 2 years of testing. Overall, 16 interval
cancers were detected in the 2 years following a negative LAT.
Dukes stage was A, B, C, and D in 3, 4, 3, and 4, respectively and
was missing in two cases. Furthermore two interval cancers were
detected within 2 years of a positive LAT followed by a negative
assessment (1 Dukes B and 1 Dukes D).
Table 1 Incidence rates (per 100.000 person-years) of colorectal cancer
in the Florence District by sex, age, and subsite in the period 1997–2002:
Tuscany Cancer Registry
Age (years) Colon Rectum Overall
Males
50–59 59.6 40.2 99.8
60–69 146.3 75.7 222.0
70–74 241.6 115.1 356.7
Females
50–59 42.9 21.0 63.9
60–69 87.6 39.6 127.2
70–74 135.6 56.4 192.0
Table 2 Age and sex distribution of subjects at the time they performed
latex agglutination test
Males Females Total
Age (years) N % N % N %
50–59 6,580 50.0 7,198 50.1 13,778 50.1
60–69 6,134 46.7 6,677 46.5 12,811 46.6
70 431 3.3 483 3.4 914 3.3
Total 13,145 100.0 14,358 100.0 27,503 100.0
Table 3 Colorectal lesions detected of Latex Agglutination Test
No. Rate 95% CI
Screening tests 27503
Positive tests 1097 4.0% 3.8–4.2
Screen positive subjects refusing
assessment
138 12.6%
Screen-detected cancers 65 2.36% 1.8–3.0
No. screen-detected advanced
adenomas
219 7.96% 6.95–9.08
No. screen-detected cancer and
advanced adenomas
284 10.3% 9.16–11.59
Interval cancers within 2 years
1 After a negative test 16 0.58% 0.33–0.94
2 After a negative test or a
positive test followed by negative
assessment
18 0.65% 0.39–1.03
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expected numbers of cancers and sensitivity estimates overall
and by time since last LAT, age, gender, location in the large bowel,
or rank of screening. Overall, 2-year sensitivity was 73.8% (CI
57.4–85.0). Although no statistically significant difference was
observed between sensitivity estimates (probably due to the small
sample size), sensitivity was higher for subsequent ranks than at
first screening (84.0 vs 57.3%, respectively, RR¼2.27, 95%
CI¼0.97–7.34) and for elderly compared to younger subjects
(79.5 vs 58.7%, respectively, RR¼2.02, 95% CI¼0.75–5.42). As
expected, sensitivity in the first year was higher than that in the
second year (82.9 vs 61.5%, respectively, RR¼0.45; 95%
CI¼0.16–1.23). No difference was evident by gender or site.
Overall, 2-year programme sensitivity was 71.5% (CI 55.0–83.1),
as shown in Table 5. No significant difference was evident by age,
gender, site, or rank. Also, the difference in sensitivity between the
first and second year (80.7 vs 59.2%, respectively, RR¼0.47, 95%
CI¼0.18–1.22) was not significant.
DISCUSSION
The present study was based on a relatively large series with cancer
registry follow-up, allowing a reliable estimate of sensitivity
according to the proportional interval cancer incidence method,
probably the most reliable available. The traditional method
Table 4 Latex test sensitivity
Person-years
Observed
interval cancers
Expected
cancers
2-year sensitivity
(1-O/E) (%)
95% confidence
intervals
Time since last test (months)
0–11 26,325 6 34.99 82.9 62.2–93.7
12–23 18,490 10 25.99 61.5 29.2–81.5
Age
50–59 20,939 7 16.95 58.7 14.9–83.4
60–70 23,876 9 44.03 79.6 61.2–90.6
Gender
Males 21,293 8 37.01 78.4 57.4–90.7
Females 23,522 8 23.96 66.6 34.2–85.6
Subsite
Colon 44,815 11 40.30 72.7 51.2–86.4
Rectum 44,815 5 20.67 75.8 43.5–92.1
Rank of screening
First 17,528 10 23.44 57.3 21.5–79.5
Subsequent 27,287 6 37.54 84.0 65.2–94.1
Total 44,815 16 60.98 73.8 57.4–85.0
Person-years, observed interval cancers, expected colorectal cancers and screening sensitivity by time since last test, age groups, gender, site, and rank of screening, according to a
2-year period of observation following a negative latex test.
Table 5 Programme sensitivity
Person-years
Observed interval
cancers
Expected
cancers
2-year sensitivity
(1-O/E) (%)
95% confidence
intervals
Time since last test (months)
0–11 27,220 7 36.29 80.7 60.3–92.2
12–23 19,127 11 26.96 59.2 27.0–79.6
Age
50–59 21,552 8 17.45 54.2 9.7–80.2
60–70 24,795 10 45.78 78.2 59.8–89.5
Gender
Males 22,108 8 38.52 79.2 59.1–91.0
Females 24,239 10 24.72 59.6 25.6–80.6
Site
Colon 46,347 13 41.80 68.9 46.8–83.4
Rectum 46,347 5 21.44 76.7 45.6–92.4
Rank of screening
First 18,232 10 24.48 59.2 24.9–80.4
Subsequent 28,115 8 38.76 79.4 59.3–91.1
Total 46,347 18 63.24 71.5 55.0–83.1
Person-years, observed interval cancers, expected colorectal cancers and screening sensitivity by time since last test, age groups, gender, subsite, and rank of screening, with a 2-
year period of observation following a negative latex test or a positive-latex test followed by a negative assessment.
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interval cancers) is open to criticism, as cancers with a long
sojourn time and unlikely to surface clinically within 2 years,
may be included among screen-detected cancers, particularly at
prevalent screen, causing a lead time bias with overestimation of
sensitivity. In fact, if we had used the traditional method the 1-year
programme sensitivity would have been 91.6% (65/65þ6)
compared to our 82.9%, and the 2-year sensitivity 80.3% (65/
65þ16) compared to our 71.5%.
Nevertheless, our sensitivity method may be subject to selection
bias. In fact, the method compares the incidence of interval CRC in
compliers with the underlying incidence expected in the general
population, assuming similar CRC incidence in compliers and
noncompliers. Should this be greater in compliers, sensitivity in
our study would be underestimated (Zappa et al, 1998).
Unfortunately, we have been unable to get relevant information,
and a study is in progress to verify the magnitude of any such bias
by measuring the observed/expected CRC incidence ratio among
noncompliers.
We regarded FOBTþ subjects who refused assessment but were
diagnosed with CRC within 1 year of the positive screen as screen
detected: in fact delayed assessment may still be motivated by (and
ascribed to) the positive screen, but becomes unlikely after 1 year,
whereas the probability of symptomatic CRC being diagnosed
increases. The latter cases were therefore excluded when assessing
programme sensitivity.
The sample size was limited, which may have prevented
statistically significant results for age, gender, and bowel site
analyses. Similarly, lack of statistical significance for sensitivity
estimates based on time since last negative test or rank of
screening may be due to the small number of events.
Although several studies have compared I-FOBT and G-FOBT
(Petrelli et al, 1994; Allison et al, 1996; Saito et al, 2000), few have
reported sensitivity estimates based on interval CRCs: Nakama
et al (1996) reported values by the traditional method, of 90.9, 83.3,
and 71.4% within 1, 2, and 3 years, respectively, using the 1-day
Monohaem, immunological test. Zappa et al (2001) used the
proportional interval cancer incidence method, and reported 1-
and 2-year sensitivity estimates for CRC for 1-day RPHA testing of
89 and 82%, respectively, whereas corresponding estimates for
3-day G-FOBT were 64 and 50%, respectively. Using the traditional
method, Launoy et al (2005) reported a 2-year sensitivity estimate
of 85% for a RPHA-derived test (Magstream) with a low-positivity
cutoff and a recall rate of 6%.
Latex agglutination test sensitivity in our study is higher than
currently reported for unhydrated G-FOBT and slightly lower than
in our previous study employing this method (Zappa et al, 2001)
using RPHA I-FOBT as a screening test (80.0 vs 89% at 1-year and
71.5 vs 82.5% at 2-year interval, respectively) or in Launoy’s study
based on a similar automated analytical method. These results may
reflect differences in analytical or statistical methods.
Other studies have assessed I-FOBT sensitivity using colono-
scopy as the gold standard: Yoshinaga et al (1995) determined LAT
sensitivity for CRC in 855 subjects undergoing colonoscopy; in 23
detected CRC, sensitivity estimates were 90 and 100% for Dukes A
and Bþ stages, respectively. Recently, Vilkin et al (2005) reported
LAT colonoscopy-based sensitivity estimates of 66.7 and 100%
with 1- and 3-day sampling, respectively. A large colonoscopy-
based study of 1-day I-FOBT (Magstream) (Morikawa et al 2005)
reported an overall sensitivity of 66%, estimates being stage –
(advanced CRC4early CRC) and site dependent (left colon4right
colon). Studies comparing FOBT results with colonoscopy for
assessing FOBT sensitivity are not comparable with our study as
they are open to lead time or overdiagnosis biases.
One possible factor negatively affecting screening programme
sensitivity could be the suboptimal quality of the assessment
phase. In our study two interval cancers were detected in FOBTþ
subjects after a negative assessment, so even though we are not
sure that CRC was present at the time of testing, these findings
probably indicate weaknesses in our programme in the recall and
assessment phases. Its sensitivity might be improved by referring
FOBTþ subjects to selected centres with high endoscopy
standards, to minimise the false-negative assessments, and by
investing resources to improve compliance.
With respect to the screening test, annual rather than biennial
testing would probably increase sensitivity by converting to
‘screen-detected’ most interval cancers occurring in the second
year, but this would not necessarily represent higher efficacy on
account of many more false–positives and unnecessary colonos-
copies. In any case, this is hardly a realistic option in Florence or
in other European countries given limited resources.
Lowering the positivity threshold (e.g. to 70ngml
 1) might have
allowed the detection of two interval cancers with LAT between 70
and 100ngml
 1: if so, sensitivity would have been raised from
73.8 to 77.0% (or 75.4% with LAT between 80 and 99ngml
 1 ).
Unfortunately, our study could not assess the corresponding
increase in advanced adenoma detection. On the other hand,
lowering the positivity cutoff to 70 or to 80ngml
 1 would have
increased recall rate from 4 to 5.9% (1612/27503) or to 5.1% (1397/
27503), respectively.
Multiple FOBT testing of 2–3 bowel movements has been
proposed as another possible option to increase sensitivity, and
2-day testing has been suggested as the most cost-effective choice
(Nakama et al, 1999; Yamamoto and Nakama, 2000). Lowering the
positivity cutoff and doubling the number of sampled bowel
movements, alone or combined, are presently being evaluated to
increase screening accuracy in a multicentre study in Italy.
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